Question - PowerPoint PPT Presentation

1 / 31
About This Presentation
Title:

Question

Description:

Can lead to kidney and liver failure. Liver cirrhosis and/or hepatocellular carcinoma (chronic) ... Symptoms of Type II Tyrosinemia. Elevated serum and plasma ... – PowerPoint PPT presentation

Number of Views:62
Avg rating:3.0/5.0
Slides: 32
Provided by: cmj
Category:

less

Transcript and Presenter's Notes

Title: Question


1
Question
  • What is NTBC, how does it function, and what does
    it prevent?

2
Tyrosinemia
  • Carolyn Jablonowski

3
Tyrosinemia
  • Inborn error in the degradation of the amino acid
    tyrosine.
  • Hereditary autosomally recessive.
  • Three types (type I, type II, type III).

4
Tyrosine and Phenylalanine


  • Tyrosine Phenylalanine
  • Structures made by Carolyn Jablonowski

5
http//upload.wikimedia.org/wikipedia/commons/thum
b/a/a4/Autorecessive.jpg/180px-Autorecessive.jpg
6
Types of Tyrosinemia
  • Type I deficiency of the enzyme
    fumarylacetoacetate hydrolase (FAH).
  • Type II deficiency of the enzyme tyrosine
    aminotransferase (TAT).
  • Type III deficiency of the enzyme
    4-hydroxyphenylpyruvate dioxygenase (HPPD).

7
Type I Tyrosinemia
  • Most common type of tyrosinemia.
  • Caused by a mutation in the FAH gene that encodes
    for the FAH enzyme.
  • Autosomally recessive
  • Can be either chronic or acute.
  • Acute infancy
  • Chronic later in life

8
FAH gene
  • Chromosome 15
  • Contains 14 exons and extends 35kb long
  • 34 mutations associated with HT1
  • All effect normal activity of FAH.

9
Symptoms of Type I Tyrosinemia
  • Failture to gain wieight or grow
  • Diarrhea and vomiting
  • Jaundice of skin and eyes
  • Cabbage-like odor
  • Increased tendency to bleed (esp. nosebleeds)
  • Can lead to kidney and liver failure
  • Liver cirrhosis and/or hepatocellular carcinoma
    (chronic).

10
Fumarylacetoacetate Hydrolase
  • FAH is the last in the series of five enzymes
    needed to catabolize tyrosine.
  • Metalloenzyme
  • Catalyzes the hydrolysis of 4-fumarylacetoacetate
    to fumarate acetoacetate.
  • Deficiency of FAH results in accumulation of
    succinylacetone, maleylacetoacetone, and
    fumarylacetoacetate.

11
FAH Catalyzed Reaction
http//umbbd.msi.umn.edu/tyr/tyr_map.html
12
HT1
http//www.newbornscreening.info/Parents/aminoacid
disorders/Images/tyrosinemia_type1.gif
13
http//www.childrenshospital.org/newenglandconsort
ium/NBS/descriptions/images/tyro3.gif
14
Type II Tyrosinemia
  • Caused by a mutation in the TAT gene that encodes
    for the hepatic (liver) TAT enzyme.
  • Autosomally recessive
  • Rare
  • Also known as Richner-Hanhard syndrome

15
TAT gene
  • Codes for tyr aminotransferase
  • 10.9kb long
  • Makes 454-AA protein weighing 50.4kDa.
  • 12 exons
  • 13 mutations associated with HT2.

16
Symptoms of Type II Tyrosinemia
  • Elevated serum and plasma tyrosine levels also.
  • Lesions of skin and eyes
  • Due to clumping of cellular tyrosine crystals.
  • Excessive tearing and abnormal sensitivity to
    light (photophobia).
  • Mental retardation (caused by elevated blood
    tyrosine levels)
  • Symptoms often begin in early childhood.

17
Tyrosine Aminotransferase
  • TAT is the enzyme involved in the first of a
    series of five reactions of tyrosine degradation.
  • In cytosol
  • Pyridoxal 5-phosphate (PLP) dependent enzyme
  • Transaminates tyrosine and
  • a-ketogluterate into p-hydrophenylpyruvate and
    glutamate.
  • Narrow substrate specificity

18
TAT Catalyzed Reaction
http//umbbd.msi.umn.edu/tyr/tyr_map.html
19
http//www.childrenshospital.org/newenglandconsort
ium/NBS/descriptions/images/tyro3.gif
20
Type III Tyrosinemia
  • Caused by a mutation in the HPPD gene that
    encodes for the enzyme HPPD.
  • Rare, autosomally recessive
  • Deficiency of 4-hydroxyphenylpyruvate dioxygenase
    (HPPD).

21
HPPD gene
  • Located on 12q24-qter
  • 14 exons
  • HT3 and Hawkinsinura both affect this gene.

22
Symptoms of Type III Tyrosinemia
  • Mild mental retardation
  • Seizures
  • Loss of balance and coordination (intermittent
    ataxia).
  • High blood and urine concentrations of tyrosine
    and HPP

23
4-Hydroxyphenylpyruvate Dioxygenase (HPPD)
  • Second enzyme involved in tyrosine catabolism
    pathway.
  • Non-heme iron oxygenase. Often forms dimers.
  • Requires Fe(II), oxygen and a alpha-keto acid
    substrate (typically alpha-ketoglutarate).

24
HPPD
http//www.uwm.edu/moran/images/HPPD.jpg
http//www.uwm.edu/moran/images/NTBC.jpg
25
Reaction Catalyzed by HPPD
http//umbbd.msi.umn.edu/tyr/tyr_map.html
26
http//www.childrenshospital.org/newenglandconsort
ium/NBS/descriptions/images/tyro3.gif
27
http//www.uwm.edu/moran/images/Tyrcatab.gif
28
Treatments
  • Dietary restriction of tyrosine and
    phenylalanine. (aim is below 500 µmol/L)
  • Treatement with NTBC (2-(2-nitro-4-trifluoro-methy
    lbenzoyl)-1,3-cyclohexanedione) to block
    metabolism.
  • Pro- Inhibitor of HPPD. NTBC structurally
    similar to HPPD
  • Pro- Protects patients from fatal, end stages of
    disease
  • Con- However, increases plasma tyrosine levels
    and requires several follow-ups.
  • Liver transplant (popular in 1980s)

29
Inhibition of HPPD
http//www.uwm.edu/moran/images/Inhibitors.gif
30
Summary
  • Tyrosinemia is an error in tyrosine catabolism.
  • Three types of tyrosinemia (I, II, and III)
  • Each is affect by a deficiency of a separate
    enzyme
  • HT1 FAH
  • HT2 TAT
  • HT3 HPPD
  • Treatments liver transplant, dietary
    restriction, inhibitors (NTBC)

31
More information
  • http//umbbd.msi.umn.edu/tyr/tyr_map.html
Write a Comment
User Comments (0)
About PowerShow.com